{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:04:39Z","timestamp":1790233479346,"version":"4.1.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Slovenian Research Agency","award":["P3-0429"],"award-info":[{"award-number":["P3-0429"]}],"id":[{"id":"https:\/\/ror.org\/059bp8k51","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Slovenian Research Agency","award":["P3-0154"],"award-info":[{"award-number":["P3-0154"]}],"id":[{"id":"https:\/\/ror.org\/059bp8k51","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer screening enables earlier cancer diagnosis and treatment. The interval between cancer diagnosis by screening and the symptomatic detection in the absence of screening is termed lead time. If a patient\u2019s tumour, detected by screening, would never surface clinically, the patient is considered overdiagnosed. Estimating these quantities is crucial for evaluating cancer screening programmes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Development<\/jats:title>\n                    <jats:p>We developed MOCCI (Minimizing Observed and Counterfactual Cancer Incidence), a novel parametric method for estimating the lead time distribution. MOCCI compares age- and calendar-stratified cancer incidence between individuals invited to screening and those not invited and estimates the lead time distribution that minimizes the incidence difference between the two groups. The probability of overdiagnosis is then estimated by comparing the model-predicted lead time with the time to death from other causes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Application<\/jats:title>\n                    <jats:p>In an application to the Slovenian breast cancer screening programme, we estimated that 30% (95% confidence interval [CI], 20% to 39%) of screen-detected cases were non-progressive and 33% (95% CI, 25% to 43%) were overdiagnosed; assuming an exponential lead time distribution for progressive cancers, the mean lead time was 1.8\u2009years (95% CI, 1.3 to 2.9).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study proposes a new method for estimating lead time and overdiagnosis. The proposed method (a) can accommodate various lead time distributions, (b) yields a lead time distribution that is aligned with the observed excess incidence arising from screening, and (c) enables the separation of different sources of overdiagnosis. The method provides stable estimates when sample sizes are large and the assumed lead time model is simple.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ije\/dyag167","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:45:37Z","timestamp":1785930337000},"source":"Crossref","is-referenced-by-count":0,"title":["Estimating lead time and overdiagnosis in cancer screening programmes: the MOCCI method"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-4475","authenticated-orcid":false,"given":"Bor","family":"Vratanar","sequence":"first","affiliation":[{"name":"Institute for Biostatistics and Medical Informatics, University of Ljubljana , Ljubljana,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Pohar Perme","sequence":"additional","affiliation":[{"name":"Institute for Biostatistics and Medical Informatics, University of Ljubljana , Ljubljana,","place":["Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026092402415383000_dyag167-B1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/bjc.2013.177","article-title":"The benefits and harms of breast cancer screening: an independent review","volume":"108","author":"Marmot","year":"2013","journal-title":"Br J Cancer"},{"key":"2026092402415383000_dyag167-B2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.breast.2013.07.046","article-title":"Bias in breast cancer research in the screening era","volume":"22","author":"Cox","year":"2013","journal-title":"Breast"},{"key":"2026092402415383000_dyag167-B3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/biomet\/56.3.601","article-title":"On the theory of screening for chronic diseases","volume":"56","author":"Zelen","year":"1969","journal-title":"Biometrika"},{"key":"2026092402415383000_dyag167-B4","doi-asserted-by":"publisher","first-page":"e2200344","DOI":"10.1002\/bimj.202200344","article-title":"Evaluating cancer screening programs using survival analysis","volume":"65","author":"Vratanar","year":"2023","journal-title":"Biom J"},{"key":"2026092402415383000_dyag167-B5","volume-title":"A Short Guide to Cancer Screening: Increase Effectiveness, Maximize Benefits and Minimize Harm.","author":"World Health Organization","year":"2022"},{"key":"2026092402415383000_dyag167-B6","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1088\/0031-9155\/55\/17\/021","article-title":"A Monte Carlo tool to simulate breast cancer screening programmes","volume":"55","author":"Forastero","year":"2010","journal-title":"Phys Med Biol"},{"key":"2026092402415383000_dyag167-B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.breast.2015.03.013","article-title":"Simulation models in population breast cancer screening: a systematic review","volume":"24","author":"Koleva-Kolarova","year":"2015","journal-title":"Breast"},{"key":"2026092402415383000_dyag167-B8","doi-asserted-by":"publisher","first-page":"e0258343","DOI":"10.1371\/journal.pone.0258343","article-title":"Quality assured implementation of the Slovenian breast cancer screening programme","volume":"16","author":"Jarm","year":"2021","journal-title":"PLoS One"},{"key":"2026092402415383000_dyag167-B9","volume-title":"Review of Sojourn Time Calculation Models Used in Breast Cancer Screening","author":"Cheung","year":"2017"},{"key":"2026092402415383000_dyag167-B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/2530739","article-title":"Simplified models of screening for chronic disease: estimation procedures from mass screening programmes","volume":"40","author":"Day","year":"1984","journal-title":"Biometrics"},{"key":"2026092402415383000_dyag167-B11","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1177\/0962280213492843","article-title":"A statistical model of breast cancer tumour growth with estimation of screening sensitivity as a function of mammographic density","volume":"25","author":"Abrahamsson","year":"2016","journal-title":"Stat Methods Med Res"},{"key":"2026092402415383000_dyag167-B12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/0962280217734583","article-title":"Modelling breast cancer tumour growth for a stable disease population","volume":"28","author":"Isheden","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2026092402415383000_dyag167-B13","doi-asserted-by":"publisher","first-page":"108270","DOI":"10.1016\/j.mbs.2019.108270","article-title":"Statistical models of tumour onset and growth for modern breast cancer screening cohorts","volume":"318","author":"Strandberg","year":"2019","journal-title":"Math Biosci"},{"key":"2026092402415383000_dyag167-B14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/cancers15030912","article-title":"Tumour growth models of breast cancer for evaluating early detection\u2014a summary and a simulation study","volume":"15","author":"Strandberg","year":"2023","journal-title":"Cancers"},{"key":"2026092402415383000_dyag167-B15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0962280219832901","article-title":"Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies","volume":"29","author":"Abrahamsson","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"2026092402415383000_dyag167-B16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.7326\/0003-4819-158-11-201306040-00008","article-title":"Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening","volume":"158","author":"Etzioni","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026092402415383000_dyag167-B17","doi-asserted-by":"publisher","first-page":"djv345","DOI":"10.1093\/jnci\/djv345","article-title":"Recognizing the limitations of cancer overdiagnosis studies: a first step towards overcoming them","volume":"108","author":"Etzioni","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2026092402415383000_dyag167-B18","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1007\/s11606-014-2867-0","article-title":"Oversimplifying overdiagnosis","volume":"29","author":"Etzioni","year":"2014","journal-title":"J Gen Intern Med"},{"key":"2026092402415383000_dyag167-B19","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1038\/bjc.2013.427","article-title":"Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis","volume":"109","author":"Zahl","year":"2013","journal-title":"Br J Cancer"},{"key":"2026092402415383000_dyag167-B20","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11606-014-2812-2","article-title":"Lead-time models should not be used to estimate overdiagnosis in cancer screening","volume":"29","author":"Zahl","year":"2014","journal-title":"J Gen Intern Med"},{"key":"2026092402415383000_dyag167-B21","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10654-020-00684-7","article-title":"Assessment of cancer screening effectiveness in the era of screening programs","volume":"35","author":"Adami","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2026092402415383000_dyag167-B22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/cancers17050742","article-title":"Evaluation of the Slovenian breast cancer screening programme: years of life gained and avoided deaths","volume":"17","author":"Tom\u0161i\u010d","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026092402415383000_dyag167-B23","doi-asserted-by":"publisher","first-page":"e0278384","DOI":"10.1371\/journal.pone.0278384","article-title":"Prognostic factors and outcomes in women with breast cancer in Slovenia in relation to step-wise implementation of organized screening","volume":"17","author":"Tom\u0161i\u010d","year":"2022","journal-title":"PLoS One"},{"key":"2026092402415383000_dyag167-B24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/raon-2017-0008","article-title":"Cancer burden in Slovenia with the time trends analysis","volume":"51","author":"Zadnik","year":"2017","journal-title":"Radiol Oncol"},{"key":"2026092402415383000_dyag167-B25","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1002\/sim.2764","article-title":"Age\u2013period\u2013cohort models for the Lexis diagram","volume":"26","author":"Carstensen","year":"2007","journal-title":"Stat Med"},{"key":"2026092402415383000_dyag167-B26","volume-title":"An Introduction to Generalized Linear Models","author":"Dobson","year":"2018"},{"key":"2026092402415383000_dyag167-B27","volume-title":"RStudio: Integrated Development Environment for R","author":"RStudio Team","year":"2022"},{"key":"2026092402415383000_dyag167-B28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/biomet\/86.3.503","article-title":"Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding","volume":"86","author":"Shen","year":"1999","journal-title":"Biometrika"}],"container-title":["International Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ije\/article-pdf\/55\/5\/dyag167\/70699500\/dyag167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ije\/article-pdf\/55\/5\/dyag167\/70699500\/dyag167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:42:01Z","timestamp":1790232121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ije\/article\/doi\/10.1093\/ije\/dyag167\/8765358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ije\/dyag167","relation":{},"ISSN":["0300-5771","1464-3685"],"issn-type":[{"value":"0300-5771","type":"print"},{"value":"1464-3685","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,18]]},"article-number":"dyag167"}}